MEDICAL RESEARCH:

PRESENTATIONS

1.    “Case Report of Atrial Septal Hematoma.”  Presented at American College of Physicians, Kansas City, Missouri, March 1987.

2.    “Decreased Rejection in Older Cardiac Transplant Patients.”  Presented at American College of Cardiology, 38th Annual Scientific Session, Anaheim, CA, March 1989.

3.    “Relationship of Histocompatibility Matching and Recipient Age to Rejection in Heart Transplantation.”  American Society of Transplant Physicians, Chicago, Illinois, May 31, 1989.

4.    “Treatment of Acute Myocardial Infarction and Use of Thrombolytic Therapy.”  St. Luke’s Medical Grand Rounds, Kansas City, Missouri, September 1990.

5.    “New Advances in the Treatment of Congestive Heart Failure.”  Presented to a group of internists and family practitioners, Kansas City, Missouri, September 1990.

6.    “New Developments in Interventional Cardiology.”  Presented at symposiumEmerging Concepts in Clinical Cardiology, Ritz Carlton Hotel, Kansas City, Missouri, August 1991.

7.    “Proper Use and Monitoring of Thrombolytic and Adjuvant Drugs.”  Presented at Primary Care of Heart Disease: Cardiovascular Risk Factors, University of Kansas Medical Center, Wichita, Kansas, October 1991.

8.    “Pathophysiology of Heart Failure: Practical Lessons to Optimize Individual Patient Management.”  Presented at Evolving Concepts in Managing Heart Failure: Controversies and Treatment Strategies for the 90’s, sponsored by Baylor College of Medicine, Houston, Texas.  Held at Allis Plaza Hotel, Kansas City, Missouri, October 1991.

9.    “New Advances in the Treatment of Heart Failure.”  Presented for Grand Rounds, Munson Army Hospital, Leavenworth, Kansas, December 1991.

10.    “Thrombolytic Therapy in Acute Myocardial Infarction.”  Update on Clinical Cardiology, sponsored by Mid-America Cardiology Associates and St. Luke’s Hospital, Kansas City, Missouri, May 1992.  Presented at the Lodge of the Four Seasons, Lake of the Ozarks, Missouri.

11.    “Update on Mortality and Treatment in Congestive Heart Failure.”  Presented May 1992 in Hiawatha, Kansas.  Sponsored by Merck, Sharp and Dohme.

12.    “Primary PTCA vs. Thrombolytic Therapy.”  Presented for Grand Rounds, Medical College of Wisconsin, Milwaukee, Wisconsin, April 1993.

13.    “Acute Infarction Management.”  Presented at the annual Spring Conference, sponsored by Mid-America Cardiology Associates and St. Luke’s Hospital at the Ritz Carlton Hotel, Kansas City, Missouri, May 1993.

14.    “Early Diagnosis of Cardiovascular Disease.”  Presented at the Visiting Professor Program of Kansas University Medical Center, Kansas City, Kansas, October 1993.

15.    “Adjunctive Therapy in Acute Myocardial Infarction.”  Presented at the annual Fall Conference, sponsored by Mid-America Cardiology Associates and St. Luke’s Hospital, Kansas City, Missouri, September 1994.

16.    “The Diagnosis and Treatment of Symptomatic Heart Failure and Asymptomatic Left Ventricular Dysfunction.”  Presented at the Bellevue Country Club, Atchison, Kansas, December 1994.  Sponsored by the Merck Working Group.

17.    “Case Studies in Cardiac Emergencies.”  Presented at the annual Management of Cardiac Emergencies Fall Conference, sponsored by Mid-America Cardiology Associates and St. Luke’s Hospital, September 1995.

18.    “Cardiovascular Clinical Case Presentations and the Medical issues that Surround Them.”  Presented at the Combined Clinical Conference on Emergency Care, Osage Beach, Missouri, August 1996.  Sponsored by the American College of Emergency Physicians.

19.    “Interactive Case Studies.”  Presented at the Update in Cardiology and Cardiovascular Emergencies Conference, sponsored by St. Luke’s Hospital and Mid-America Cardiology Associates, September 1996.

20.    “Gene Therapy.”  Grand Rounds, Shawnee Mission Medical Center, February 4, 2004.

21.    MAOPS national convention (Missouri Association of Osteopathic Physicians and Surgeons) Chateau on the Lake, Branson, MO Women and Cardiovascular Disease “What’s the big deal?,” May 1, 2008.

22.    Medical Education program sponsored by Boston Scientific Hilton, Monterey, CA Evaluation and Treatment of Sudden Cardiac Death “Bridging Clinical Trials to Real World Practice,” June 22, 2008.

23.    Medical Education program sponsored by Boston Scientific New Orleans, LA 21st Century Mangement of the Complex HF Patient,  “ Sudden Cardiac Arrest: Who’s At Risk?,” October 28, 2008.

24.    MAOPS National Convention Chateau on the Lake, Branson, MO Evaluation and Treatment of Sudden Cardiac Death “Bridging Clinical Trials to Real World Practice,” April 30, 2009.

25.    “Congestive Heart Failure.”  Presented at Missouri State University, June 15, 2010.

26.    Panel sponsored by CoxHeath, “PFO:  Medical Management versus Surgery,” August 15, 2010.

27.    “Congestive Heart Failure.”  Presented at Missouri State University, June 16, 2011.

28.    “Congestive Heart Failure.”  Presented at Missouri State University, June 13, 2012.

29.    “IVUS Guided PCI: TAXUS Liberte Post Approval Study poster.”  Presented at the CRT Conference on February 25, 2013 in Washington, DC.

30.    “ Congestive Heart Failure.”  Presented at Missouri State University, September 16, 2013.

MANUSCRIPTS

1.    Rowe, SK, Porter CB, Atrial Septal Hematoma: Two-dimensional echocardiographic findings after blunt chest trauma.  Am Heart J 115:65-652, 1987.

2.    Pollack, MS, Ballantyne CM, Payton-Ross C, Cocanougher B., Rowe SK, Grant GJ, Farmer JA, Noon GP, Weilbaecher DG, Flores D, Young JB.  HLA match and other immunological parameters in relation to survival, rejection severity, and accelerated coronary artery disease after heart transplant.  Clin Transplantation 4:269-275, 1990.

3.    Rowe, SK, Kleiman NS, Cocanougher B, Smart FW, Minor ST, Raizner AE, Henry PD, Roberts R, Pratt CM, Young JB.  Effects of intracoronary acetylcholine infusion early versus late after heart transplant.  Transplantation Proceedings 23(1): 1193-1197, 1991.

4.    Raizner AE, Rowe SK. Averting occlusion and restenosis in post-PTCA patients: Strategies to reduce early and late complications.  J. Critical Illness 5:921-931, 1990.

5.    Vacek JL, Rosamond TL, Stites HW, Rowe SK, Robuck W, Dittmeier G, Beauchamp GD.  Comparison of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery for multivessel coronary artery disease.  Am J Cardiology 69:592-597, 1992.

6.    McSweyn DJ, Vacek JL, Robuck OW, Berenbom LD, Porter CB, Kramer PH, Genton, RE, Rowe SK, Beauchamp, GD.  The use of percutaneous transluminal coronary angioplasty in myocardial infarction.  Texas Heart Institute Journal 18:263-8, 1991.

7.   Beauchamp GD, Vacek JL, Robuck W, Genton RE, Rowe, SK, Kramer, PH.  “The 18K balloon angioplasty catheter: A new low-profile device with enhanced operating characteristics.”  Medtronic, Inc. 1991.

8.    Handlin, LR, Kindred, LH, Beauchamp GD, Vacek JL, Rowe SK.  Reversible left ventricular dysfunction after subarachnoid hemorrhage.  Am Heart J 126:235-240, 1993.

9.    Rowe, Steven K. Cryptogenic stroke.  Greene County Medical Society Journal, February 2011.

10.    Sherif F. Nagueh, MD; Bertron M. Groves, MD; Leonard Schwartz, MD; Karen M. Smith, MD; Andrew Wang, MD; Richard G. Bach, MD; Christopher Nielsen, MD; Ferdinand Leya, MD; John M. Buergler, MD; Steven K. Rowe, MD; Anna Woo, MD; Yolanda Munoz Maldonado, PhD; William H. Spencer, III, MD. : Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy: Amulticenter North American Registry.  Volume 58 November, 22, 2011.

11.    Rowe, Steven K. : CRT-59 IVUS Guided PCI: Taxus Libertē Post Approval Study.  JACC Cardiovascular Interventions, Feburary 2013.  Volume 6, Issue 2_S.

ABSTRACTS

1.    Rowe, SK, Young JB, Noon GP, DeBakey, ME.  Decreased rejection in older cardiac transplant patients.  J Am Coll Cardiology 12:38A, 1989.

2.    Pollack MS, Ballantyne CM, Rowe SK, Grant GJ, Farmer JA, Payton-Ross C, Thornton B, Noon GP, Weilbaecher DG, Flores D., Young JB.  The relationship of HLA match to survival of heart transplantation patients. Clinical Histocompatibility Workshop, Palm Springs Invitation, 1989, Terasaki P (ed).  One Lambda, Inc., Los Angeles, California, 1989.

3.    Pollack, MS, Ballantyne CM, Rowe SK, Grant GJ, Farmer JA, Payton-Ross C, Thornton B., Noon GP, Weilbaecher DG, Flores D., Young JB.  The relationship of HLA match to rejection episodes in heart transplantation patients.  Clinical Histocompatibility Workshop, Palm Springs Invitation, 1989, Terasaki P (ed).  One Lambda, Inc., Los Angeles, California, 1989, page 92.

4.    Pollack, MS, Ballantyne CM, Rowe SK, Grant GJ, Farmer JA, Payton-Ross C, Thornton B., Noon GP, Weilbaecher DG, Flores D., Young JB.  The relationship of pretransplant PRA levels to rejection episodes in cardiac transplant patients.  Clinical Histocompatibility Workshop, Palm Springs Invitation, 1989, Terasaki P (ed). One Lambda, Inc., Los Angeles, California, 1989, page 93.

5.    Pollack, MS, Ballantyne CM, Rowe SK, Grant GJ, Farmer JA, Payton-Ross C, Thornton B., Noon GP, Weilbaecher DG, Flores D., Young JB.  The relationship of pre-transplant PRA levels to rejection episodes in cardiac transplant patients.  Clinical Histocompatibility Workshop, Palm Springs Invitation, 1989, Terasaki P (ed). One Lambda, Inc., Los Angeles, California, 1989, page 9.

6.    Pollack, MS, Ballantyne CM, Rowe SK, Grant GJ, Farmer JA, Payton-Ross C, Thornton B, Noon GP, Weilbaecher DG, Flores D, Young JB.  Relationship of positive pre-transplant crossmatch tests to rejection episodes in cardiac transplant patients.  Clinical Histocompatibility Workshop, Palm Springs Invitation, 1989, Terasaki P (ed).  One Lambda, Inc., Los Angeles, CA 1989.

7.    Ballantyne CM, Rowe SK, Payton-Ross C., Cocanougher B, Pollack MS, Weilbaecher DG, Smart FW, Noon GP, Sekela ME, Young JB.  The relationship of attenuated rejection severity in older cardiac transplant patients to immunologic parameters and immunosuppressive protocol.  Presented, in part, at the American College of Cardiology Scientific Sessions, March 1989, Anaheim, CA.

8.    Ballantyne CM, Rowe SK, Pollack MS, Farmer JA, Payton-Ross C, Thornton B, Noon GP, Weilbaecher DG, Young JB. Relationship of histocompatibility matching and recipient age to rejection in heart transplant patients. Clin Transplantation 4:269-275, 1990.

9.    Nagueh, Sherif, Rowe, Steven K.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy: Multicenter North American Registry.  Journal of the American College of Cardiology, publication pending.

10.    Steven K. Rowe; TS Bowman MD, MPH; David P. Lee MD; Kirk N. Garratt MScMD; IVUS Guided PCI: TAXUS Liberte Post Approval Study; poster submission to TCT and CRT 2012.

RESEARCH PROTOCOLS, 1999 TO PRESENT:

1.    Berlex Angiogenesis Phase 1, 2 and 3.  A multi-center research trial sponsored by Berlex Laboratories Inc. to find 1) whether gene therapy using Ad5FGF-4, an investigational/experimental procedure, can be safely administered and 2) whether such experimental therapy can stimulate the growth of new blood vessels in the heart and benefit patients with angina pectoris.

2.    Alcohol Ablation for obstructive cardiomyopathy in conjunction with Baylor University.

3.    AFm Registry for patients with atrial fibrillation in conjunction with Vitatron/Medtronic.

4.    Microvolt T-wave Alternans for detection of sudden cardiac death with Cambridge Heart/Medtronic.

5.    Winner” Cutting Balloon registry in association with Boston Scientific Corporation.

6.    “A Prospective, Multicenter, Non-Randomized Registry to Evaluate the Safety and Efficacy of the Medtronic AVE Bridgeä SE Self-Expanding Stent Delivery System in Subjects with De Novo and Restenotic Lesions of the Iliac Arteries” MEDTRONIC AVE, INC.  (“ISIS-SE TRIAL”) February 2003 – Present.

7.    “A Randomized, Double-blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, Slow Release Formulation, in the Treatment of High Risk De Novo Coronary Lesions” BOSTON SCIENTIFIC CORPORATION (“TAXUS V DE NOVO TRIAL”) March 2003 to Present

8.    “A Phase III, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529, 414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared with Atorvastatin Alone, in Subjects with Angiographically Documented Coronary Heart Disease.”  Pfizer, Inc.  November 2003 to present.

9.    ”Proximal Protection during Saphenous Vein Graft Intervention using the Proxisä Embolic Protection System: A Randomized, Prospective, Multi-center Clinical Trial” (PROXIMAL) Velocimed, Inc.  March 2004 to present.

10.    ”Registration of Cardiac Resynchronization Therapy-US” (RESTORE-US). Medtronic, Inc. March 2004 to present.

 11.    STRADIVARIUS EFC 5827 – Randomized, Multicenter, double- blind, placebo controlled, two- arm parrallel group trisl of rimonabant 20-mg, od, for inhibition of atherosclerosis progression assessed by IVUS (Intra Ultrasounds) in overweight patients with clustering risk factors.

12.    A randomized comparison of AngiomaxÒ (bivalirudin) versus heparin (enoxaparin or unfractionated heparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation (ACUITY)

13.    A Study of the EvalveÔ Cardiovascular Valve Repair System (CVRS): Endovascular Valve Edge to Edge Repair Study (EVEREST II)

14.    A Study of the variation in recovery in the role of gender on outcomes of young acute myocardial infarction patients (VIRGO) 

15.    A Study of the longitudinal surveillance registry of the ACUITY Spiral Lead (LSR of ACUITY Spiral)

16.    A prospective, multi-center study designed to observe clinical outcomes in patients receiving the TAXUS Liberté-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen. (DAPT Study) (TAXUS Liberte).

17.    Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy Initiation.  This is a multi-center, randomized, blinded, parallel-group study designed to assess if incorporating genotype testing results of CYP2C9 and VKORC1 gene variants into a Warfarin dosing protocol (WARFARIN).

18.    GORE HELEX Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO).  This is a phase III, prospective, randomized, multi-center, multinational clinical trial designed to demonstrate that patent foramen ovale closure with the Gore Helex Septal Occluder plus antiplatelet medical management is safe and effective and reduces the risk of recurrent stroke or imaging-confirmed transient ischemic attack when compared to antiplatelet medical management alone in patients with a PFO and history of cryptogenic stroke or imaging-confirmed TIA (REDUCE).

19.    A prospective, open-label, multi-center study designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System (PROMUS Element Plus).

20.    The REVEAL AF study is a prospective, single arm, open-label, multi-center, postmarket interventional study to evaluate the incidence of AF in patients that are suspected to be at  high risk of having AF.  Up to 450 subjects are planned to be enrolled into the study, to have approximately 400 patients implanted with the Reveal ICM (REVEAL AF).

21.    IVUS Guided PCI: TAXUS Liberte Post Approval Study poster. Presented at the CRT Conference on February 25, 2013 in Washington, DC.